SCHEMBL7125560

SCHEMBL7125560

CCOc1ccc(C2CCC(OC)CC2C(=O)c2cc(OC)ccc2OC)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.42
KDM4E B2RXH2 5/20 0.42
TSHR P16473 3/20 0.42
MAPK1 P28482 2/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 2/20 0.42
USP2 O75604 1/20 0.42
LMNA P02545 4/20 0.42
ALDH1A1 P00352 2/20 0.40
HTT P42858 3/20 0.40
NPSR1 Q6W5P4 3/20 0.40
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
ALOX15 P16050 2/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7122241 0.94 MAPT (0.42) MAPTKDM4ETSHRMAPK1HPGD
SCHEMBL7123051 0.93 MAPT (0.46) MAPTKDM4ETSHRMAPK1HPGD
SCHEMBL7127040 0.92 MAPT (0.46) MAPTKDM4ELMNAALDH1A1HTT
SCHEMBL7127212 0.89 MAPT (0.49) MAPTKDM4ETSHRMAPK1HPGD
SCHEMBL7116872 0.87 MAPT (0.44) MAPTKDM4ETSHRMAPK1HPGD
SCHEMBL7124473 0.86 TUBB1 (0.47) MAPTKDM4ETSHRMAPK1USP2
SCHEMBL6853125 0.86 TUBB4A (0.44) MAPTKDM4ETSHRMAPK1HPGD
SCHEMBL7125930 0.85 MAPT (0.46) MAPTKDM4ELMNAALDH1A1HTT
SCHEMBL6859917 0.85 TUBB4A (0.44) MAPTKDM4ELMNAALDH1A1HTT
SCHEMBL6859990 0.84 POLB (0.45) MAPTKDM4ETSHRMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2003-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof ABL1, MCL1, AHR MAPT 4538/4885KDM4E 1243/4885TSHR 3499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.